

ROMIPLOSTIM AND ELTROMBOPAG IN THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA

Martínez Lazcano MT, Alonso Serrano E.
Pharmacy Service
Hospital del Vinalopo.Elche. Spain



OBJECTIVE

✓ Describe the use of Romiplostim and Eltrombopag in the treatment of idiopathic thrombocytopenic purpura (ITP) in clinical practice.

METHODS

✗ Descriptive observational study (January 2011-February 2013) of patients with refractory ITP treated with romiplostim or eltrombopag.

RESULTS

Table 1. Variables analyzed

- ✓ Demographic data
- ✓ Previous treatments/splenectomy status
- ✓ Response to treatment
 - *Platelet count $\geq 50 \times 10^9 / L$ for at least 8 weeks
- ✓ Number of weeks with continuous response
- ✓ Clinically significant bleeding
- ✓ Need for rescue medication
- ✓ Adverse effect profile

Characteristics	Results
Patients	
Age-yr	N = 5
Female sex-no. (%)	62 ± 12.65
Splenectomy no./total no.	100 1/5
Previous treatment-no.	5
Glucocorticoid	5
IV immune globulin	5
Rituximab	4
≥ 2 previous treatments	5

Romiplostim patients	Results
Patients	N = 4
Duration of treatment-mo.	
Median	23.5 ± 20.5
Range	3-44
Dose- mcg/kg	
Median	4
Range	1-10
Response to treatment – no.	N = 3
Duration of response-wk	48 ± 39,1

Safety profile

Bleeding events-no. ≥ grade 2	0
Other adverse events-no.	0

Eltrombopag patients

Results

Patient 1 → 3 months treatment; no response → switch to romiplostim
Patient 2 → no response to romiplostim → switch to eltrombopag → response to treatment (levels $\geq 50 \times 10^9 / L$)

REFERENCES

1. David J. Kuter et al. Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. *N Engl J Med* 2010;363:1889-99.
2. James B. Bussel et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009; 373: 641–48

CONCLUSIONS

- ✓ Romiplostim and eltrombopag have proven effective and safe in patients with refractory ITP.
- ✓ Both drugs can be considered therapeutic equivalents.